RayzeBio, Inc.

Overview

• IndustryPharmaceutical Preparations¹
• HeadquartersSan Diego, California¹
• Incorporated inDE²
• Business address5505 Morehouse Drive, Suite 300, San Diego, Ca 92121²
• Filer category, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

RayzeBio, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led RayzeBio, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerKenneth Song Sep 14, 2023 to Feb 27, 2024³
• PresidentKenneth Song Sep 14, 2023 to Feb 27, 2024³
• Chief financial officerArvind Kush Sep 14, 2023 to Feb 27, 2024⁴

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerAubrey Haddach named Sep 22, 2022¹⁴
• DirectorAaron Kantoff named Sep 22, 2022¹⁴
• DirectorAlex Rosen named Sep 22, 2022¹⁴
• DirectorJerel Davis named Sep 22, 2022¹⁴

Timeline

1. Feb 26, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer¹⁵
2. Dec 26, 20238-K Entered a material agreement; Executive or director change; Regulation FD disclosure¹⁶
3. Nov 13, 20238-K Results of operations¹⁷
4. Nov 1, 20238-K Executive or director change¹⁸
5. Sep 19, 20238-K Bylaws or fiscal year changed; Other events¹⁹
6. Sep 14, 2023New chief executive Kenneth Song becomes CEO³

Calendar

When it reported results

1. Nov 13, 2023Reported quarterly or annual results¹⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

96 filings to the SEC since October 2021: 1 quarterly reports, 5 major events, 41 insider forms, 7 large holders, 1 private raises, 41 other. The latest 20:

1. Mar 7, 202415-12G EDGAR
2. Feb 28, 20244 EDGAR
3. Feb 28, 20244 EDGAR
4. Feb 28, 2024SC 13G/A EDGAR
5. Feb 27, 20244 EDGAR
6. Feb 27, 20244 EDGAR
7. Feb 27, 20244 EDGAR
8. Feb 27, 20244 EDGAR
9. Feb 27, 20244 EDGAR
10. Feb 27, 20244 EDGAR
11. Feb 27, 20244 EDGAR
12. Feb 27, 20244 EDGAR
13. Feb 27, 20244 EDGAR
14. Feb 27, 20244 EDGAR
15. Feb 26, 2024S-8 POS EDGAR
16. Feb 26, 20248-K EDGAR
17. Feb 23, 2024SC 14D9/A EDGAR
18. Feb 16, 2024CORRESP EDGAR
19. Feb 14, 2024SC 14D9/A EDGAR
20. Feb 14, 2024SC 13G/A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• VIKING GLOBAL INVESTORS LPSC 13G/A, 2 filings Sep 21, 2023 to Feb 28, 2024²⁰
• Venrock Healthcare Capital Partners III, L.P.SC 13G/A, 2 filings Sep 29, 2023 to Feb 14, 2024²¹
• venBio Global Strategic Fund III, L.P.SC 13G, 1 filing Feb 9, 2024²²
• Versant Venture Capital VII, L.P.SC 13G, 1 filing Feb 8, 2024²³
• Wellington Management CompanySC 13G, 1 filing Feb 8, 2024²⁴

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Aug 25, 2022Raised $167.9 million in a private offering of equity¹⁴ Form D: 18 investors so far Form D

SEC filer profile

How RayzeBio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARRayzeBio, Inc.¹
• CIK0001825367
• Filer status<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address5505 Morehouse Drive, Suite 300, San Diego, CA 92121¹
• Phone(619) 937-2754¹
• Shares outstanding59,919,502 as of Nov 7, 2023²⁵
• On EDGAR sinceNov 9, 2020¹
• Filings105 in all: 4 (24), 3 (17), UPLOAD (8), CORRESP (6), 8-K (5), SC 13G (5), D (4), DRS/A (3)¹
  All 30 form types

  DRSLTR (3), SC 14D9/A (3), SC TO-T/A (3), SC14D9C (3), SEC STAFF LETTER (3), SC 13G/A (2), 10-Q (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-8 (1), S-8 POS (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

• Latest filingsQuarterly report (10-Q) Nov 13, 2023
  Latest 8-K (8-K) Feb 26, 2024